GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NCT01134484: Phase 3 - VELCADE-Thal-Dex (VTD) vs Thal-Dex (TD) Incorporated Into Double ASCT NDMM
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
A Meta-Analysis: Tandem Vs Single Autologous Hematopoietic Cell Transplantation Myeloma - JNCI 2009
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
Single versus double autologous stem-cell transplantation for multiple myeloma
IFM 9502 trial: 200 mg/m(2) melphalan Vs 8 Gy TBI + 140 mg/m(2) melphalan as conditioning Blood 2002
Results of autologous stem cell transplant in multiple myeloma patients with renal failure